Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Demographic characteristics of MS patients in Poland's Upper Silesia region.
Challenges and opportunities in designing clinical trials for neuromyelitis optica.
Nitric oxide plays a dual role in the oxidative injury of cultured rat microglia but not astroglia.
Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).
Outcomes after Microvascular Decompression for Patients with Trigeminal Neuralgia and Suspected Multiple Sclerosis.
Pixantrone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease.
Unethical for neurologists not to offer patients with multiple sclerosis chemotherapy with autologous stem cell support.
[Oral treatments in multiple sclerosis].
[Symptomatic therapy in multiple sclerosis].
Subretinal angiostrongyliasis-induced optic neuritis.
Comparison of Vitamin D3 Serum Levels in New Diagnosed Patients with Multiple Sclerosis versus Their Healthy Relatives.
Glatiramer Acetate 40 Mg/Ml Three Times A Week for The Treatment of Relapsing Forms of Multiple Sclerosis: Potential Cost Benefits of A Regimen With Infrequent Injections Which May Minimise Switching to The Newly-Introduced First-Line and Second-Line Dise
Cerebrospinal fluid analysis in the context of CNS demyelinating diseases.
Targeting the B7 Family of Co-Stimulatory Molecules : Successes and Challenges.
Exploring the overlap between multiple sclerosis, tumefactive demyelination and Baló's concentric sclerosis.
Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis.
Working memory performance of early MS patients correlates inversely with modularity increases in resting state functional connectivity networks.
Walking Speed and Brain Glucose Uptake are Uncoupled in Patients with Multiple Sclerosis.
Neuromyelitis optica spectrum disorder and multiple sclerosis: Differentiation by a multimodal approach.
Altered molecular expression of TLR-signaling pathways affects the steady-state release of IL-12p70 and IFN-α in patients with relapsing-remitting multiple sclerosis.
[MRI and CSF features in neuromyelitis optica].
Pediatric multiple sclerosis.
Fatigue at time of CIS is an independent predictor of a subsequent diagnosis of multiple sclerosis.
Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts - Is There a Place for Baseline-to-Treatment Studies in MS?
Retinal Nerve Fiber Layer Thickness, Brain Atrophy, and Disability in Multiple Sclerosis Patients.
Pages
« first
‹ previous
…
544
545
546
547
548
549
550
551
552
…
next ›
last »